Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing schedules of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma
To evaluate the progression free survival (PFS) and overall survival (OS) in patients with advanced MEL receiving either MK-3475 or IPI.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Study investigating a new medicine - Doravirine in patients diagnosed with HIV-1 without previous treatment for this disease. Neither the doctor or patient will know the treatment group. All the patients will be treated with Truvada or Epzicom/Kivexa, some of the patients will be treated in addition with Doravirine, while the others will be treated in addition with Darunavir plus Ritonavir
Base Study: To evaluate the antiretroviral activity of MK-1439 100 mg q.d., compared to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as measured by...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug (Sitagliptin) in patients with Type 2 Diabetes. Ispitivanje radi procjene sigurnosti i ucinkovitosti dodatne terapije s MK-3102 u usporedbi s dodatnom primjenom sitagliptina kod ispitanika sa secernom bolesti tipa 2
1. To assess the effect of treatment with MK-3102 compared with Sitagliptin on A1C. 2. To assess the safety and tolerability of MK-3102.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Etoricoxib with naproxen in ankylosing spondylitis
Objective 1: To compare the effects of etoricoxib 90 mg once daily to naproxen 1000 mg in the treatment of ankylosing spondylitis as measured by Spinal Pain Intensity (0- to 100-mm VAS, Question 2 of ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Study of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus
In pediatric patients (ages 10-17 years) with T2DM with inadequate glycemic control: (1) after 20 weeks, to assess the effect of treatment with sitagliptin compared with placebo on A1C (2) to assess t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Phase III CDK in refractory CLL Hármas fázisú CDK inhibitor, refrakter CLL-ben
To demonstrate superiority in progression-free survival of dinaciclib compared to ofatumumab in CLL subjects with del 17 p, or in the overall CLL population (those with del17p and those without del17p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Raltegravir/Lamivudine Drug Interaction Study
Assess the plasma pharmacokinetic profiles of raltegravir and lamivudine after administration of MK-0518B (Formulation #6) and coadministration of the marketed Isentress 400 mg and Epivir 150 mg table...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Phase II Study of Pembrolizumab in Subjects with Gastric Cancer
- To determine the safety and tolerability of pembrolizumab administered at 200 mg Q3W dosing as monotherapy and in combination with cisplatin and 5-fluorouracil or cisplatin and capecitabine. - To es...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Patients will be randomly assigned to receive an experimental study medication (MK-3475) or a commonly used chemotherapy medication. The purpose of this study is learn more about the safety and effect of MK-3475 compared to other chemotherapy medication in patients who have skin cancer that has spread to other part of the body
1) To evaluate the PFS in patients with IPI-refractory advanced MEL receiving either pembrolizumab or chemotherapy. 2) To evaluate the OS in patients with IPI-refractory advanced MEL receiving eith...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Examine the Efficacy and Safety of a Single Dose of Intravenous MK-0517. Studio per esaminare l'efficacia e la sicurezza di una singola dose da 150 mg di fosaprepitant dimeglumina per via endovenosa per la prevenzione di nausea e vomito indotti da chemioterapia associati a chemioterapia moderatamente emetogena
To compare the single-dose fosaprepitant 150 mg regimen to the control regimen in terms of the proportion of patients with Complete Response (no vomiting and no use of rescue medication) from 25 to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant